1. Editor's page

   EditorialNotes Pages: 297 - 297

2. Biological meaning of stage and grade in human breast cancer: Review and hypothesis

   • Francis E. Sharkey

   Review Pages: 299 - 322

3. Tumor cell proliferation and sequential chemotherapy after partial tumor resection in C3H/HeJ mammary tumors

   • Paul G. Braunschweiger
   • Lewis M. Schiffer
   • Sergio Betancourt

   Report Pages: 323 - 329

4. Tumor-associated prostaglandins in patients with primary breast cancer: Relationship to clinical parameters

   • Amy Fulton
   • Larry Roi
   • Michael J. Brennan

   Report Pages: 331 - 337

5. Quantitative comparison of estradiol and progesterone receptor contents of primary and metastatic human breast tumors in relation to response to endocrine treatment

   • R. J. B. King
   • J. F. Stewart
   • J. L. Hayward

   Report Pages: 339 - 346

6. Considerations in the design and evaluation of cytotoxic estrogens

   • John A. Katzenellenbogen
   • Benita S. Katzenellenbogen

   Scandinavian Breast Cancer Symposium Pages: 347 - 353

7. Nutritional aspects of the epidemiology of breast cancer

   • F. de Waard

   Scandinavian Breast Cancer Symposium Pages: 355 - 361

8. The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancer

   • John Patterson
   • Barry Furr
   • Linda Battersby

   Scandinavian Breast Cancer Symposium Pages: 363 - 374

9. Pharmacologic suppression of estrogens with aminoglutethimide as treatment of advanced breast carcinoma

   • Richard J. Santen
   • Elliott Badder
   • Samuel A. Wells

   Scandinavian Breast Cancer Symposium Pages: 375 - 383

10. Some properties of a plasminogen activating factor in human breast cancer cytosol and its relation to steroid receptors

    • Thor Thorsen

    Scandinavian Breast Cancer Symposium Pages: 385 - 390

11. Perioperative adjuvant chemotherapy vs postoperative chemotherapy for one year

    • Roar Nissen-Meyer
    • Herman Høst
    • Torsten Norin

    Scandinavian Breast Cancer Symposium Pages: 391 - 394

12. Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels

    • Carsten Rose
    • Karen Theilade
    • Henning T. Mouridsen

    Scandinavian Breast Cancer Symposium Pages: 395 - 400

13. Monoclonal antibodies applied to primary human breast carcinoma: Relationship to menopausal status, lymph node status, and steroid hormone receptor content

    • Birgitte Bruun Rasmussen
    • John Hilkens
    • Carsten Rose

    Scandinavian Breast Cancer Symposium Pages: 401 - 405

14. Adjuvant endocrine therapy of breast cancer

    • R. D. Rubens

    Scandinavian Breast Cancer Symposium Pages: 407 - 410

15. 12 versus 6 cycles of adjuvant CMF in breast cancer

    • Anaxagoras Papaioannou
    • George Papageorgiou

    Correspondence Pages: 411 - 411

16. 12 versus 6 cycles of adjuvant CMF in breast cancer — Reply

    • Pinuccia Valagussa
    • Gianni Bonadonna

    Correspondence Pages: 411 - 412

17. An unusual fatal marrow suppression from very brief adjuvant chemotherapy for Stage II breast cancer

    • Alexander R. Stevens
    • James M. Thornbery

    Correspondence Pages: 412 - 414

18. The influence of parity on estrogen and progesterone receptors in primary breast cancer

    • Susan M. Thorpe
    • Carsten Rose
    • Birgitte Bruun Rasmussen

    Correspondence Pages: 414 - 416